Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer

Is adjuvant chemoradiotherapy more effective than chemotherapy alone in patients with gastric cancer and T4 or node-positive disease following D2 gastrectomy (ie, gastrectomy with D2 lymphadenectomy)?In this randomized clinical trial involving 620 patients, adding radiotherapy to adjuvant S-1 plus oxaliplatin (SOX) chemotherapy after D2 gastrectomy did not significantly improve disease-free survival or overall survival compared with SOX alone.These findings suggest that routine intensification with postoperative radiotherapy added to adjuvant SOX may not be warranted after D2 R0 resection for T4 or node-positive gastric cancer.

Corresponding Author: Feng Bi, MD, Division of Abdominal Tumor Multimodality Treatment, West China Hospital, Sichuan University, Sichuan, China; State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Sichuan, China, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan Province, China (bifeng@scu.edu.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.